Wu Tian Hong, Brandt Christopher Filtenborg, Scheike Thomas, Burisch Johan, Jeppesen Palle Bekker
Department of Intestinal Failure and Liver Diseases, Rigshospitalet, Copenhagen, Denmark.
Department of Public Health, Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
J Crohns Colitis. 2025 Jan 11;19(1). doi: 10.1093/ecco-jcc/jjae114.
The natural history of Crohn's disease leading to intestinal failure is not well characterised. This study aims to describe the clinical course of Crohn's disease preceding intestinal failure and to compare disease course and burden between Crohn's disease patients with and without intestinal failure.
Patients with Crohn's disease complicated by intestinal failure from Rigshospitalet, Copenhagen [n = 182] and a nationwide Danish Crohn's disease cohort without intestinal failure [n = 22,845] were included. Using nationwide registries in Denmark, disease course was determined from hospitalisations, surgeries, and outpatient medications, and disease burden was determined from employment and mortality data.
The 10-year cumulative incidence of intestinal failure following Crohn's disease diagnosis declined from 2.7% prior to 1980 to 0.2% after 2000. Compared with Crohn's disease patients without intestinal failure, those with intestinal failure experienced significantly longer duration of severe disease [50 vs 19 years per 100 patient-years, p < 0.01], secondary to greater corticosteroid use [71% vs 60%, p = 0.02], inpatient contacts [98% vs 55%, p < 0.01], and abdominal surgeries [99% vs 48%, p < 0.01]. However, exposure to biologics was not different between the two groups [20.4% vs 21%, p = 0.95], and duration on biologics was shorter in Crohn's disease patients with intestinal failure [2068 vs 4126 days per 100 patient-years, p = 0.02]. Standard mortality ratio in Crohn's disease patients with intestinal failure was 3.66 (97.5% confidence interval [CI] 2.79, 4.72].
Patients with Crohn's disease complicated by intestinal failure experienced a more persistently severe preceding course of Crohn's disease but were not more likely to be treated with biological therapy.
导致肠衰竭的克罗恩病自然史尚未得到充分描述。本研究旨在描述肠衰竭前克罗恩病的临床病程,并比较有无肠衰竭的克罗恩病患者的病程及疾病负担。
纳入来自哥本哈根里格霍斯医院的182例并发肠衰竭的克罗恩病患者以及丹麦全国范围内22845例无肠衰竭的克罗恩病队列患者。利用丹麦全国登记处的数据,根据住院、手术和门诊用药情况确定病程,根据就业和死亡率数据确定疾病负担。
克罗恩病诊断后肠衰竭的10年累积发病率从1980年前的2.7%降至2000年后的0.2%。与无肠衰竭的克罗恩病患者相比,有肠衰竭的患者经历严重疾病的持续时间显著更长(每100患者年分别为50年和19年,p<0.01),这是由于使用糖皮质激素更多(71%对60%,p=0.02)、住院接触更多(98%对55%,p<0.01)以及腹部手术更多(99%对48%,p<0.01)。然而,两组之间生物制剂的暴露情况无差异(20.4%对21%,p=0.95),且有肠衰竭的克罗恩病患者使用生物制剂的持续时间更短(每100患者年分别为2068天和4126天,p=0.02)。有肠衰竭的克罗恩病患者的标准化死亡率为3.66(97.5%置信区间[CI]2.79,4.72)。
并发肠衰竭的克罗恩病患者在肠衰竭前经历的克罗恩病病程更为严重且持续时间更长,但接受生物治疗的可能性并不更高。